Category: News

ONL Therapeutics Gets Federal Grant of $1 Million Crain’s Company also raises $1 million to fund drug for patients with retinal detachments… Read the Article

After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials Xconomy ONL Therapeutics, the Ann Arbor, MI-based biotech startup working on sight-preserving therapies for patients with retinal diseases, is one step closer to clinical trials, thanks to a cash infusion from the National Eye Institute (NEI)…. Read the Article

Ocular Surgery NewsMay 18, 2017 ONL Therapeutics closes $4.25 million in Series A funding ONL Therapeutics has closed $4.25 million in Series A funding for preclinical development of its lead therapeutic candidate, ONL1204, designed to treat retinal detachment, according to a company press release. The funding, which came from investors including Novartis, the University of…

ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program Xconomy Detroit – 7/6/15 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to…

ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment ANN ARBOR, MI – November 12, 2014 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced that the company has been awarded a $1.37 million Small…

SBIR Award, $1M Investment Get ONL Therapeutics to Clinical Trials Xconomy Detroit – 11/12/14 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out biopharmaceutical startup working on sight-preserving therapies for retinal diseases, announced today that it has won a $1.3 million Small Business Innovation Research (SBIR) Phase II award from the National Eye Institute. Read the Article

Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine Retina Today – October 2014By Pravin U. Dugel, M.D. Leading retinal specialist and industry opinion leader Pravin U. Dugel, MD, discusses ONL Therapeutics’ core technology and its significant potential to treat retinal disease. Read the Article

ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo Crain’s Detroit – 10/02/14by Tom HendersonONL Therapeutics was named the first place winner in the Emerging Company Showcase at the MichBio Expo winning a $2,500 first prize.  See article in Crain’s Detroit below: Read the Article

ONL ANNOUNCES LEADERSHIP CHANGES ONL ANNOUNCES LEADERSHIP CHANGESOctober 29, 2013 Ann Arbor, Mich. (October 29, 2013) — ONL Therapeutics today announced the appointments of John Freshley as Chief Executive Officer and Anna Schwendeman as Vice President of Preclinical Development. These appointments follow the sad loss of Co-Founder and former CEO Raili Kerppola to adrenal cancer…